期刊文献+

miR-144脂质体复合物体外抑制肝癌细胞增殖和侵袭能力及对裸鼠种植肿瘤的抑制作用初步研究 被引量:4

Preliminary observation of miR-144 liposomes on inhibition of proliferation, migration and invasion of liver cancer cells in vitro and in vivo
下载PDF
导出
摘要 目的研究mi-RNA-144脂质体复合物对HepG2和SMMC-7721细胞增殖、迁移和侵袭的影响,并观察其在体内的抑瘤作用。方法通过薄膜分散法制备DOTMA阳离子脂质体,与miR-144孵育得到miR-144脂质体复合物,通过摄取和转染实验确定DOTMP脂质体与miR-144的体积质量比;观察miR-144脂质体复合物对HepG2和SMMC-7721细胞杀伤、迁移和侵袭能力的影响。在裸鼠肝脏种植肿瘤模型,观察miR-144脂质体复合物的抑瘤作用。结果选择DOTMP脂质体与miR-144的体积质量比为3:1,得到的miR-144脂质体复合物粒径在200 nm左右,其多分散性指数(PDI)小于0.3;DOTMP脂质体与质粒的体积/质量比(μl/μg)为3:1时,转染效率最高(P<0.05);随着孵育时间的延长,miR-144脂质体复合物对SMMC-7721细胞和HepG2细胞的杀伤作用均增强(P<0.05);经miR-144脂质体复合物处理过的HepG2细胞和SMMC-7721细胞迁移和侵袭距离均显著缩短(P<0.01);与对照组比,经过miR-144脂质体复合物处理的肿瘤细胞接种肿瘤直径显著缩小(P<0.05)。结论 miR-144脂质体能够在体外和体内抑制肝癌细胞的侵袭,具有很大的应用前景。 Objective To observe the inhibition of miR-144 liposomes on proliferation,migration and invasion of liver cancer cells in vitro and in vivo. Methods DOTMA cationic liposomes were prepared by thin film dispersion method,and miR-144 liposomes were prepared by incubating liposome with miR-144. The volume to mass ratio of DOTMP liposomes and miR-144 were determined by uptake and transfection experiments. The cytotoxicity of liposome on HepG2 and SMMC-7721 cells,impacts on cell migration and invasiveness and the inhibitory effect on implanted tumor sizes in nude mice were observed. Results When the volume mass ratio of DOTMP liposomes and miR-144 was 3:1,the particle size of miR-144 liposome complex was about 200 nm with the PDI of less than 0.3;the transfection efficiency of DOTMP liposomes was the highest when the volume/mass ratio of plasmids and miR-144(mu l/g) was 3:1(P<0.05);the HepG2 and SMMC-7721 cells intook much more miR-144 liposome complex as incubation prolonged(P<0.05);the migration distance of HepG2 and SMMC-7721 cells were both significantly shorten by miR-144 liposome complex as compared with in the control group(P <0.05);the volumes of implanted miR-144 liposome complex intervened HepG2 and SMMC-7721 cell tumors were significantly smaller than in the control group(P <0.05). Conclusion MiR-144 liposomes might inhibit the activity of hepatocellular carcinoma cells in vitro and in vivo,which worth further investigation.
作者 许达峰 周开伦 李灼日 武金才 陈鑫苹 张震生 郑进方 王雨 刘向梅 Xu Dafeng;Zhou Kailun;Li Zhuori(Department of Cholangiopancreatic Surgery,Provincial General Hospital,Haikou 570031,Hainan Province,China)
出处 《实用肝脏病杂志》 CAS 2019年第1期25-28,共4页 Journal of Practical Hepatology
基金 海南省自然科学基金资助项目(编号:20158274)
关键词 肝细胞癌 miR-144脂质体 HEPG2 SMMC-7721细胞 裸鼠 Hepatoma miR-144 liposomes HepG2 SMMC-7721 cells Nude mice
  • 相关文献

参考文献2

二级参考文献227

  • 1Jian-Yong Lei,Wen-Tao Wang,Lu-Nan Yan.“Metroticket” predictor for assessing liver transplantation to treat hepatocellular carcinoma:A single-center analysis in China's Mainland[J].World Journal of Gastroenterology,2013,19(44):8093-8098. 被引量:5
  • 2F. Y.Yao,L.Xiao,N. M.Bass,R.Kerlan,N. L.Ascher,J. P.Roberts.Liver Transplantation for Hepatocellular Carcinoma: Validation of the UCSF‐Expanded Criteria Based on Preoperative Imaging[J].American Journal of Transplantation.2007(11)
  • 3Pierre-Alain Clavien,Mickael Lesurtel,Patrick MM Bossuyt,Gregory J Gores,Bernard Langer,Arnaud Perrier.Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report[J]. Lancet Oncology . 2012 (1)
  • 4Josep M. Llovet,Jordi Bruix.Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival[J]. Hepatology . 2003 (2)
  • 5Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao-Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Shenglong Ye,Tsai-Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,Dimitris Voliotis,Zhongzhen Guan.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J].Lancet Oncology.2009(1)
  • 6European Association for the Study of the Liver,European Organisation for Research and Treatment of Cancer.EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma[J].Journal of Hepatology.2012(4)
  • 7Riccardo Lencioni,Josep Llovet.Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma[J].Semin Liver Dis.2010(01)
  • 8F.Xavier Bosch,Josepa Ribes,Mireia Díaz,Ramon Cléries.Primary liver cancer: Worldwide incidence and trends[J].Gastroenterology.2004(5)
  • 9Francesca Bravi,Cristina Bosetti,Alessandra Tavani,Silvano Gallus,Carlo La Vecchia.Coffee Reduces Risk for Hepatocellular Carcinoma: An Updated Meta-Analysis[J].Clinical Gastroenterology and Hepatology.2013
  • 10E. Terzi,R. Golfieri,F. Piscaglia,M. Galassi,A. Dazzi,S. Leoni,E. Giampalma,M. Renzulli,L. Bolondi.Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”[J].Journal of Hepatology.2012(6)

共引文献90

同被引文献20

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部